Home

Andrew Cheng

CIK 1778307 · President and CEO · last filed 2026-05-26

Andrew Cheng is a President and CEO who has filed 89 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for VERA, was dated May 26, 2026. Across all open-market trades the lifetime net is −$43.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $583.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$583.7K

Companies

3

Total Filings

89

Lifetime Open-Market Net

-$43.39M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VERA Director 17,488 $33.38 $583.7K $0 7 2026-05-26
Akero Therapeutics, Inc. (AKRO) Delisted President and CEO 0 $54.65 $0 -$43.39M 72 2025-12-09
ABUS Director — $4.42 — $0 3 2021-06-07

Recent Filings

89 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-26 VERA Grant (A) — $0 EDGAR
2025-12-09 Akero Therapeutics, Inc. (AKRO) Delisted Disp (D) −436,837 $0 EDGAR
2025-11-21 Akero Therapeutics, Inc. (AKRO) Delisted Gift (G) −74,538 $0 EDGAR
2025-11-13 Akero Therapeutics, Inc. (AKRO) Delisted Gift (G) −14,739 $0 EDGAR
2025-10-14 Akero Therapeutics, Inc. (AKRO) Delisted Mixed — -$1.02M EDGAR
2025-10-09 Akero Therapeutics, Inc. (AKRO) Delisted Exer (M) +52,212 $32.1K EDGAR
2025-09-12 Akero Therapeutics, Inc. (AKRO) Delisted Mixed −16,855 -$1.25M EDGAR
2025-09-10 Akero Therapeutics, Inc. (AKRO) Delisted Notice (144) −90,000 -$4.02M EDGAR
2025-08-13 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −30,000 -$1.46M EDGAR
2025-07-11 Akero Therapeutics, Inc. (AKRO) Delisted Sell (S) −30,000 -$1.53M EDGAR
Showing 1–10 of 89
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.